ADAM10 and colorectal carcinoma: Autoantibodies against ADAM10 were demonstrated to possess a high diagnostic ability of CRC (AUC > 65%), whereas the follow-up of stage III CRC patients from 2 to 73 months revealed the association of high ADAM10 plasma autoantibodies with an increased recurrence-free survival rate (from 23 to 55 months) (160).